Teriparatide 560MCG/2.24ML pen 2.24ML
Ended Awarded
- Contract number
- SPE2DB26FAUAJ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,214
Award facts
- Contract value 100% obligated
- $1,213.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $1,213.76 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Teriparatide 560mcg/2.24ml pens. The delivery order, issued on October 29, 2025, with an ultimate completion date of October 30, 2025, was issued without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. This award represents one of numerous delivery orders DMS Pharmaceutical Group has received from the Defense Logistics Agency's Medical Supply Chain division, reflecting the company's established role as a critical supplier within the federal pharmaceutical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, awarded in November 2025 with a $499.999 billion ceiling and completion date of December 31, 2036, authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide. The PPV-G GEN V program represents a $30.3 billion acquisition strategy, with DMS Pharmaceutical Group positioned as one of multiple regional prime vendor contractors providing diverse pharmaceutical and medical supply requirements for the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FAUAJ?
SPE2DB26FAUAJ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FAUAJ worth?
The government has obligated $1,214 on SPE2DB26FAUAJ.
Is contract SPE2DB26FAUAJ an order under another contract?
Yes. SPE2DB26FAUAJ is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB26FAUAJ competed?
The extent of competition for SPE2DB26FAUAJ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award